AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10389751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 2116
Study 10389751 — intervention group
Group type: COMPARATOR
Intervention: Screened and control arms of the NBSS
Number of subjects: 2116
Study 8594240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy during pregnancy and/or during labor and delivery
Number of subjects: 92
Study 8594240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy during gestation
Number of subjects: 92
Study 8594240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 92
Study 8487326 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (60 mg/m2) and Fluorouracil (600 mg/m2) (MF)
Number of subjects: 255
Study 8487326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (100 mg/m2) orally on days 1‐14 plus MF (CMF)
Number of subjects: 255
Study 3031714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg ACTH 4-10
Number of subjects: 14
Study 3031714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29673306 — intervention group
Group type: EXPERIMENTAL
Intervention: Date SMART program
Number of subjects: 109
Study 29673306 — intervention group
Group type: COMPARATOR
Intervention: Knowledge Only (KO) comparison
Number of subjects: 109
Study 29607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐directional spiral
Number of subjects: 34
Study 29607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentulo spiral
Number of subjects: 34
Study 29607843 — intervention group
Group type: COMPARATOR
Intervention: Incremental technique
Number of subjects: 34
Study 29607843 — intervention group
Group type: COMPARATOR
Intervention: Past inject
Number of subjects: 34
Study 27680029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine 500 IU hCG in up to 0.5 ml normal saline
Number of subjects: 158
Study 27680029 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine 0.5 ml normal saline
Number of subjects: 158
Study 24913343 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative stepped care
Number of subjects: 180
Study 24913343 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 180
Study 22387758 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy task condition with 3 letters (positive probes)
Number of subjects: 0
Study 22387758 — intervention group
Group type: EXPERIMENTAL
Intervention: Demanding task condition with 5 letters (probe items)
Number of subjects: 0
Study 22387758 — intervention group
Group type: EXPERIMENTAL
Intervention: High memory load condition
Number of subjects: 0
Study 20136765 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training (FG; n=19)
Number of subjects: 37
Study 20136765 — intervention group
Group type: EXPERIMENTAL
Intervention: Running training (RG; n=18)
Number of subjects: 37
Study 18217157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD)
Number of subjects: 41
Study 18217157 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 300 mg LD / 75 mg MD
Number of subjects: 41
Study 18217157 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg LD / 75 mg MD
Number of subjects: 41
Study 15452187 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U subcutaneous weekly for 16 weeks
Number of subjects: 344
Study 15452187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 15452187 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 344
Study 15452187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (irrespective of treatment arm)
Number of subjects: 344
Study 12854748 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral posteroventral pallidotomy (PVP) - left side
Number of subjects: 36
Study 12854748 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral posteroventral pallidotomy (PVP) - right side
Number of subjects: 36
Study 12854748 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral posteroventral pallidotomy (PVP)
Number of subjects: 36
Study 12854748 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no surgery)
Number of subjects: 36
Study 10811451 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-MAb-LL2 administered in a twice weekly pattern with 20 mg of unlabeled LL2 prior to each dose
Number of subjects: 21
Study 10811451 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-MAb-LL2
Number of subjects: 21
Study 8897877 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (5‐HT3 antagonist)
Number of subjects: 0
Study 8897877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1808368 — intervention group
Group type: EXPERIMENTAL
Intervention: External-Self Dual Reinforcement (ESR)
Number of subjects: 132
Study 1808368 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of Self Reinforcement after External-Self Dual Reinforcement (delta SR)
Number of subjects: 132
Study 1808368 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of External Reinforcement following Dual Reinforcement (delta ER)
Number of subjects: 132
Study 1808368 — intervention group
Group type: COMPARATOR
Intervention: External Reinforcement (ER)
Number of subjects: 132
Study 1808368 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of External-Self Dual Reinforcement (delta ESR)
Number of subjects: 132
Study 6800270 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline tapering and discontinuation (double-blind)
Number of subjects: 17
Study 6800270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study 6800270 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline tapering and discontinuation
Number of subjects: 17
Study 31917714 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation present
Number of subjects: 3845
Study 31351660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 400 mg
Number of subjects: 220
Study 31351660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 800 mg
Number of subjects: 220
Study 31351660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cligosiban 1200 mg
Number of subjects: 220
Study 31351660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 28204722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg, titrated intravenously)
Number of subjects: 0
Study 28204722 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg additional)
Number of subjects: 0
Study 25691036 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox treatment for 1 year
Number of subjects: 1530
Study 25691036 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LPI
Number of subjects: 1530
Study 25691036 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin saturation (TfSat)
Number of subjects: 1530
Study 25691036 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin (SF)
Number of subjects: 1530
Study 25346838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume evacuator
Number of subjects: 0
Study 25346838 — intervention group
Group type: COMPARATOR
Intervention: No high-volume evacuator
Number of subjects: 0
Study 22027216 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hip abductor and external rotator strengthening (3 times per week for 8 weeks)
Number of subjects: 28
Study 22027216 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hip abductor and external rotator strengthening (exercise group)
Number of subjects: 28
Study 19460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter identification task with pairs of adjacent letters presented at varying distances from fixation.
Number of subjects: 0
Study 19460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Model of encoded position of each letter as independent and Gaussian distributed.
Number of subjects: 0
Study 19460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter size variation in the task.
Number of subjects: 0
Study 19460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a pre-cue in the task.
Number of subjects: 0
Study 17502630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography screening for AAA
Number of subjects: 67770
Study 15345157 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (Dermabond)
Number of subjects: 25
Study 15345157 — intervention group
Group type: COMPARATOR
Intervention: Absorbable suture (3/0 polydiaxanone)
Number of subjects: 25
Study 11475442 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta-1a 30 mcg
Number of subjects: 802
Study 11475442 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta-1a 60 mcg
Number of subjects: 802
Study 11475442 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with and without gadolinium-enhancement
Number of subjects: 802
Study 9440756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus leucovorin plus levamisole for 6 months
Number of subjects: 891
Study 9440756 — intervention group
Group type: COMPARATOR
Intervention: Standard 5-FU plus levamisole for 6 months
Number of subjects: 891
Study 9440756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-course 5-FU plus leucovorin plus levamisole for 12 months
Number of subjects: 891
Study 9440756 — intervention group
Group type: COMPARATOR
Intervention: Standard 5-FU plus levamisole for 12 months
Number of subjects: 891
Study 7989637 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MIF‐1 (Pro‐Leu‐Gly‐NH2)
Number of subjects: 20
Study 7989637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 2465562 — intervention group
Group type: EXPERIMENTAL
Intervention: Histaglobin-Triplex (combination of histamine and human gammaglobulin)
Number of subjects: 40
Study 2465562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (human gammaglobulins without histamine)
Number of subjects: 40
Study 2465562 — intervention group
Group type: EXPERIMENTAL
Intervention: Histaglobin-Triplex
Number of subjects: 40
Study 2465562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 47281 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 24
Study 47281 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 24
Study 47281 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 24
Study 47281 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 1000 mg
Number of subjects: 24
Study 47281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30508293 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL water drink
Number of subjects: 8300
Study 30508293 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 mL water drink
Number of subjects: 8300
Study 30508293 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (pre-donation arm exercise)
Number of subjects: 8300
Study 30508293 — intervention group
Group type: COMPARATOR
Intervention: Standard care controls
Number of subjects: 8300
Study 28051800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1,200 mg/day)
Number of subjects: 112
Study 28051800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (30-120 mL/day)
Number of subjects: 112
Study 28051800 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 112
Study 26030318 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 17
Study 24184427 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy
Number of subjects: 62
Study 24184427 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 62
Study 21870174 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Diet
Number of subjects: 131
Study 21870174 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain-enriched diet (WGED)
Number of subjects: 131
Study 21870174 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 131
Study 18469253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-poor FVJ
Number of subjects: 4358
Study 18469253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits, vitamin C-rich FVJ, FVJ ascorbic acid, and fiber-poor FVJ categories
Number of subjects: 4358
Study 16487230 — intervention group
Group type: EXPERIMENTAL
Intervention: Course in cognitive therapeutic skills (5th year training copy)
Number of subjects: 85
Study 16487230 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal curriculum)
Number of subjects: 85
Study 12713193 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with both biological parents
Number of subjects: 34001
Study 12713193 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a single mother
Number of subjects: 34001
Study 12713193 — intervention group
Group type: EXPERIMENTAL
Intervention: National beer sales figures and societal patterns of heavy adolescent alcohol use
Number of subjects: 34001
Study 10859283 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab-reteplase 5+5 U
Number of subjects: 241
Study 10859283 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab-reteplase 5+5 U with 60 U/kg heparin
Number of subjects: 241
Study 10859283 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab-reteplase 5+5 U with 40 U/kg heparin
Number of subjects: 241
Study 10859283 — intervention group
Group type: COMPARATOR
Intervention: reteplase alone
Number of subjects: 241
Study 10859283 — intervention group
Group type: COMPARATOR
Intervention: abciximab alone
Number of subjects: 241
Study 10859283 — intervention group
Group type: COMPARATOR
Intervention: standard-dose heparin
Number of subjects: 241
Study 10859283 — intervention group
Group type: COMPARATOR
Intervention: low-dose heparin
Number of subjects: 241
Study 9168578 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 87
Study 9168578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 8247594 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (1 g twice a day for two months)
Number of subjects: 60
Study 8247594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8247594 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan
Number of subjects: 60
Study 3756056 — intervention group
Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthetic based on etomidate plus increments of fentanyl
Number of subjects: 55
Study 3756056 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitrous oxide with i.v. fentanyl increments
Number of subjects: 55
Study 31987231 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg)
Number of subjects: 93
Study 31987231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU/day)
Number of subjects: 93
Study 31987231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 31987231 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and Vitamin E
Number of subjects: 93
Study 29371379 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP+IMT
Number of subjects: 150
Study 29371379 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 150
Study 27253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review intervention
Number of subjects: 0
Study 27253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing acceptance
Number of subjects: 0
Study 27253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal patient care with repeated reviews
Number of subjects: 0
Study 27253380 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity and low kidney function
Number of subjects: 0
Study 24629504 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for managing fatigue over 3 weeks
Number of subjects: 160
Study 24629504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 23046525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 50 IU/kg
Number of subjects: 77
Study 23046525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 100 IU/kg
Number of subjects: 77
Study 23046525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 150 IU/kg
Number of subjects: 77
Study 23046525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 77
Study 23046525 — intervention group
Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 77
Study 20157745 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene and 1 microg alfacalcidol (RA)/day
Number of subjects: 24
Study 20157745 — intervention group
Group type: COMPARATOR
Intervention: 1 microg alfacalcidol alone (A)/day
Number of subjects: 24
Study 18601844 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Chinese herbal medicine‐based intervention
Number of subjects: 0
Study 18601844 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compound‐based TCM drug intervention
Number of subjects: 0
Study 16164451 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 385
Study 12515836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Number of subjects: 20
Study 12515836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11758061 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotically assisted CABG of the left internal thoracic artery (LITA) to the left anterior descending artery (LAD)
Number of subjects: 18
Study 8672388 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 vol% sevoflurane
Number of subjects: 52
Study 8672388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 vol% isoflurane
Number of subjects: 52
Study 8672388 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 8672388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 vol% sevoflurane
Number of subjects: 52
Study 8672388 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 vol% sevoflurane
Number of subjects: 52
Study 8672388 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 vol% isoflurane
Number of subjects: 52
Study 8672388 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 vol% isoflurane
Number of subjects: 52
Study 1378646 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nomegestrol acetate combined with 17-beta-estradiol by transcutaneous route
Number of subjects: 0
Study 6389217 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (Locoid) 0.1% cream
Number of subjects: 40
Study 6389217 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (Uniderm) 1% cream
Number of subjects: 40
Study 29685482 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized physical therapy
Number of subjects: 220
Study 30463763 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Roux loop (SRLG)
Number of subjects: 166
Study 30463763 — intervention group
Group type: COMPARATOR
Intervention: Long Roux loop (LRLG)
Number of subjects: 166
Study 26848872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (training on injury prevention strategies)
Number of subjects: 55
Study 26848872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 55
Study 25184864 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3)
Number of subjects: 2310
Study 25184864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2310
Study 22276647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with highest nutrient concentration (palm toco concentrate and algae biomass containing astaxanthin)
Number of subjects: 4
Study 22276647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with highest nutrient concentration
Number of subjects: 4
Study 22276647 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrhenius accelerated stability study
Number of subjects: 4
Study 20408890 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete immunization schedule with commercial vaccines
Number of subjects: 26
Study 20408890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20408890 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART interruption
Number of subjects: 26
Study 17505460 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids administration (antepartum or postpartum)
Number of subjects: 0
Study 17505460 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids administration
Number of subjects: 0
Study 15848504 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (SRL) + Cyclosporine (CsA), n = 98
Number of subjects: 167
Study 15848504 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL), n = 69
Number of subjects: 167
Study 11950803 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 240
Study 11950803 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 240
Study 9466503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound dilution (Transonics Hemodialysis Monitor, Transonics Systems Incorporated) (TRANS)
Number of subjects: 64
Study 9466503 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential conductivity (Hemodynamic Monitor, GAMBRO Healthcare Incorporated) (HDM)
Number of subjects: 64
Study 9466503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit dilution (Crit‐Line Monitor, In‐Line Diagnostics) (CRIT)
Number of subjects: 64
Study 9466503 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Qa values
Number of subjects: 64
Study 7881669 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg.kg‐1 in 250 ml 5% dextrose intravenously over 15 min
Number of subjects: 38
Study 7881669 — intervention group
Group type: COMPARATOR
Intervention: Placebo in 250 ml 5% dextrose intravenously over 15 min
Number of subjects: 38
Study 2404433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rynatan (8 mg chlorpheniramine tannate, 25 mg pyrilamine tannate, 25 mg phenylephrine tannate)
Number of subjects: 104
Study 2404433 — intervention group
Group type: EXPERIMENTAL
Intervention: Rynatan
Number of subjects: 104